VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium: The Takeda Oncology Company Pipeline Agents to be Featured at American Society of Hematology Annual Meeting

Published: Nov 06, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that more than 60 abstracts from studies involving five molecules in the Company’s portfolio have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 8 – 11 in Atlanta, Georgia. The abstracts include oral and poster presentations across a range of hematological diseases.

Back to news